H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

127.00DKK
7:40am EDT
Price Change (% chg)

kr.0.50 (+0.40%)
Prev Close
kr.126.50
Open
kr.127.00
Day's High
kr.127.50
Day's Low
kr.125.80
Volume
45,821
Avg. Vol
239,687
52-wk High
kr.173.60
52-wk Low
kr.109.50

LUN.CO

Chart for LUN.CO

About

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. The Company is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, including Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease... (more)

Overall

Beta: 0.63
Market Cap (Mil.): kr.24,841.91
Shares Outstanding (Mil.): 196.38
Dividend: 2.77
Yield (%): 2.19

Financials

  LUN.CO Industry Sector
P/E (TTM): 208.01 35.59 35.92
EPS (TTM): 0.61 -- --
ROI: 0.69 18.98 18.26
ROE: 0.87 19.75 19.14
Search Stocks

BRIEF-Otsuka and Lundbeck submit drug application to FDA

COPENHAGEN, July 14 - H. Lundbeck * Otsuka and lundbeck submit new drug application (NDA) to the United States Food and Drug Administration (FDA) for brexpiprazole for the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression * The NDA is supported by seven completed clinical Phase 2 or 3 studies in proposed indications * Clinical development program included more than 6,500 individuals, including more than 5,300 who received brexpiprazole Sou

14 Jul 2014

NORDIC STOCKS-Factors to watch on July 10

OSLO, July 10 - The following stocks may be affected by newspaper reports and other factors on Thursday:

10 Jul 2014

UK cost agency backs Lundbeck alcohol dependency drug

LONDON - A novel drug to fight alcohol dependency has been endorsed for use on Britain's state health service by the country's cost-effectiveness watchdog NICE in a boost to its Danish maker Lundbeck.

09 Jul 2014

UK cost agency backs Lundbeck alcohol dependency drug

LONDON, July 10 - A novel drug to fight alcohol dependency has been endorsed for use on Britain's state health service by the country's cost-effectiveness watchdog NICE in a boost to its Danish maker Lundbeck.

09 Jul 2014

BRIEF-Lundbeck provides update on the development programme for desmoteplase

STOCKHOLM, June 27 - H Lundbeck A/S : * Lundbeck provides update on the development program for desmoteplase * Says the study did not meet the primary endpoint * Says will now consult with clinical and regulatory experts about the future

27 Jun 2014

BRIEF-Lundbeck completes tender offer of Chelsea Therapeutics

COPENHAGEN, June 23 - H. Lundbeck : * Has successfully completed tender offer for Chelsea Therapeutics * Merger expected to close today, 62.5 percent of outstanding shares tendered and Notices of Guaranteed Delivery delivered for 16.1 percent of outstanding shares * By acquiring Chelsea Therapeutics, Lundbeck gains the rights to Chelsea Therapeutics' recently FDA-approved product, Northera (droxidopa), which is expected to be launched later in 2014 * Says orphan neurology drug Nor

23 Jun 2014

BRIEF-Lundbeck study shows Brintellix improves cognitive function

COPENHAGEN, June 16 - Denmark's H Lundbeck A/S said: * New results from the CONNECT study shows that Brintellix (vortioxetine) improves cognitive performance and function in adult patients with major depression * Brintellix 10-20 mg/day met the primary study endpoint in adult patients with major depression and showed a statistically significant improvement in cognitive performance as measured by the Digit Symbol Substitution Test versus placebo * The study results are consistent wi

16 Jun 2014

BRIEF-Lundbeck offers to buy outstanding shares in Chelsea

COPENHAGEN, May 23 - Danish pharmaceutical company H Lundbeck said on Friday: * Commences tender offer for all outstanding shares of Chelsea Therapeutics * Offer to purchase all outstanding shares of Chelsea for 6.44 dollars per share in cash and Contingent Value Rights that may pay up to an additional 1.50 dollar per share upon achievement of certain sales milestones * The tender offer period will expire at 12:00 midnight (New York City time) on 20 June 2014, unless otherwise exten

23 May 2014

Lundbeck to buy U.S. firm Chelsea Therapeutics for up to $658 million

COPENHAGEN - Danish pharmaceutical company H. Lundbeck is to buy Chelsea Therapeutics for up to $658 million in a deal that would give it the rights to the U.S. firm's neurology drug Northera.

08 May 2014

CORRECTED-UPDATE 1-Lundbeck to buy U.S. firm Chelsea Therapeutics for up to $658 mln

(Corrected to say that Northera drug could become Lundbeck's most valuable neurological drug in the United States, not the most valuable drug in Lundbeck's pipeline)

08 May 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks